BioSpace

Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026

At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on Merck and Moderna’s personalized cancer vaccine, Summit and Akeso’s PD-1xVEGF bispecific therapy, and a host of antibody-drug conjugates.

By BioSpace

1 min read
Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights